Different expression of S 100 A 11 in normal ovarian epithelium , serous benign / borderline tumor , and low-grade serous ovarian carcinoma

Yanli Li,Suqing Liu,Chengcheng Hu,Wei Xu,Sufang Wu
2016-01-01
Abstract:S100A11 is an EF hand-type Ca2+-binding protein involved in various biological processes such as cell proliferation and differentiation. It acts as either a tumor suppressor or promoter in many different types of cancers. Low-grade serous ovarian carcinoma (LGSC) is a less common subtype of ovarian cancer which is considered to develop in a stepwise fashion. To further understand the role of S100A11 in LGSC, we investigated immunohistochemical expression of S100A11 on a series of benign, borderline and malignant serous tumors as well as normal ovarian epithelia. Moreover, the association between S100A11 expression and various clinical pathological parameters of LGSC was also evaluated. The results showed that S100A11 expression was significantly increased from normal ovarian epithelium to benign and borderline tumors, and then to LGSC. S100A11 overexpression was associated with more advanced FIGO stage (P = 0.018) and increased residual disease (P = 0.043) in LGSC. Higher S100A11 expression was associated with poorer overall survival (P = 0.043), while multivariate analysis revealed S100A11 to be an independent prognostic factor for overall survival (P = 0.011) in patients with LGSC. Results suggest that S100A11 expression may contribute to the initiation, promotion and progression of LGSC; it might be a useful biomarker for the outcome prediction of LGSC.
What problem does this paper attempt to address?